---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-24-000097"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:48:03.144381+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BeiGene Q2 2024 revenue up 56% to $929M; achieves first non-GAAP operating income

## Summary
- Total revenue of $929 million, up 56% YoY; BRUKINSA global sales $637M (+107% YoY).
- GAAP operating loss narrowed to $107M from $319M; non-GAAP operating income of $48M (positive inflection point).
- Proposes redomicile from Cayman Islands to Switzerland; opens $800M biologics facility in New Jersey.
- Pipeline: advancing sonrotoclax (BCL2i) and BGB-16673 (BTK degrader); over 15 solid tumor molecules in development.
- BRUKINSA leads BTKi class in U.S. new patient starts across all approved indications.

## SEC filing metadata
- accession: 0001651308-24-000097
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000097/0001651308-24-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000097/bgne-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-24-000097
- JSON: https://secwatch.observer/filing/0001651308-24-000097.json
- Plain text: https://secwatch.observer/filing/0001651308-24-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.